Journal
MOLECULES
Volume 23, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/molecules23123124
Keywords
structure-activity relationship; protein-mRNA interactions; G-quadruplexes; PhenDC3; pyridostatin; EBNA1; Epstein-Barr virus (EBV)
Funding
- La Ligue contre le cancer
- La Ligue contre le cancer CSIRGO
- Fondation ARC
- Institut National du cancer (INCa)
- Cancerfonden [16059]
- Cancerforskningsfondedn Norr
- Vetenskapsradet
- project MEYS-NPS [I-L01413]
- European Union under the European Regional Development Fund
- [P206/12/G151]
Ask authors/readers for more resources
Protein-RNA interactions (PRIs) control pivotal steps in RNA biogenesis, regulate multiple physiological and pathological cellular networks, and are emerging as important drug targets. However, targeting of specific protein-RNA interactions for therapeutic developments is still poorly advanced. Studies and manipulation of these interactions are technically challenging and in vitro drug screening assays are often hampered due to the complexity of RNA structures. The binding of nucleolin (NCL) to a G-quadruplex (G4) structure in the messenger RNA (mRNA) of the Epstein-Barr virus (EBV)-encoded EBNA1 has emerged as an interesting therapeutic target to interfere with immune evasion of EBV-associated cancers. Using the NCL-EBNA1 mRNA interaction as a model, we describe a quantitative proximity ligation assay (PLA)-based in cellulo approach to determine the structure activity relationship of small chemical G4 ligands. Our results show how different G4 ligands have different effects on NCL binding to G4 of the EBNA1 mRNA and highlight the importance of in-cellulo screening assays for targeting RNA structure-dependent interactions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available